Source: Eur Respir J 2013; 42: 893-894
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vonk-Noordegraaf Anton, Boerrigter Bart G.. Sildenafil: a definitive NO in COPD. Eur Respir J 2013; 42: 893-894

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroids in COPD: the clinical evidence Source: Eur Respir J 2015; 45: 525-537 Year: 2015 Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010 Inhaled treatment of COPD: A delphi consensus statement Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Inhaled corticosteroids in COPD: a case in favour Source: Eur Respir J 2009; 34: 10-12 Year: 2009 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Inhaled corticosteroids in COPD: the case against Source: Eur Respir J 2009; 34: 13-16 Year: 2009 Beta-blockers and COPD: the show must go on Source: Eur Respir J 2016; 48: 600-603 Year: 2016 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009 Weaning from inhaled corticosteroids in COPD: the evidence Source: Eur Respir J 2015; 46: 1232-1235 Year: 2015 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014